NRX Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
NRXP$2.36-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statement of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years ended December 31, | ||||||
| · 2023 · 2022 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: · · | ||||||
| Net loss | | $(30,150) | | $(39,754) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Depreciation expense | | 5 | | 4 | ||
| Stock-based compensation | | 387 | | 3,628 | ||
| Change in fair value of warrant liabilities | | | (20) | | | (255) |
| Change in fair value of earnout cash liability | | | — | | | (4,582) |
| Change in fair value of convertible promissory note | | | 2,707 | | | 505 |
| Non-cash settlement expense | | 250 | | — | ||
| Increases (decreases) in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other assets | | 3,040 | | (632) | ||
| Accounts payable | | 2,655 | | (1,611) | ||
| Accrued expenses and other liabilities | | (531) | | 2,942 | ||
| Net cash used in operating activities | | | (21,657) | | | (39,755) |
| CASH FLOWS FROM INVESTING ACTIVITIES | | | | | | |
| Purchase of computer equipment | | | (3) | | | (10) |
| Net cash used in investing activities | | | (3) | | | (10) |
| CASH FLOWS FROM FINANCING ACTIVITIES | | | | | | |
| Proceeds from convertible notes payable, net of discount | | | — | | | 10,020 |
| Proceeds from stock option exercise | | | — | | | 10 |
| Repayment of note payable | | | — | | | (518) |
| Repayment of convertible note | | | (3,092) | | | — |
| Repayment of insurance loan | | | (943) | | | — |
| Proceeds from issuance of insurance loan | | | 943 | | | — |
| Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs | | | 1,171 | | | — |
| Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs | | | 8,122 | | | 22,702 |
| Net cash provided by financing activities | | 6,201 | | | 32,214 | |
| | | | | | | |
| Net decrease in cash and cash equivalents | | (15,459) | | | (7,551) | |
| Cash and cash equivalents at beginning of year | | 20,054 | | | 27,605 | |
| Cash and cash equivalents at end of year | | $4,595 | | $20,054 | ||
| Supplemental disclosure of cash flow information: | | | | | ||
| Cash paid for interest | | $885 | | $— | ||
| Cash paid for taxes | | $— | | $— | ||
| Non-cash investing and financing activities | | | | | ||
| Issuance of common stock as principal and interest repayment for convertible notes | | $982 | | $— | ||
| Issuance of common stock warrants as offering costs | | $75 | | $726 | ||
| Issuance of common stock for consulting services | | $— | | $17 | ||
| Issuance of common stock for settlement of accrued liability | | $250 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.